Projects per year
Personal profile
Biography
Dr. Willem (Joost) Lesterhuis is an NHMRC RD Wright Research Fellow with the School of Biomedical Sciences and the National Centre for Asbestos Related Diseases at the University of Western Australia. He has a background as a dual-trained medical oncologist and basic researcher in tumour immunology and cancer biology.
His research focuses on identifying new effective treatment combinations in cancer, in particular in mesothelioma, and focusing on immunotherapy. Using network analysis of gene expression data from tumours in mouse models and patient samples, his research aims to identify predictive biomarkers for clinical efficacy of immuno-oncology drugs, as well as new context-specific targets for pharmacological intervention and novel combination treatments.
His research combines several lines of science; systems biology, network science, cancer biology, pharmacology/drug discovery, immunology and translational oncology.
Research
Current research projects include:
1- Combining chemotherapy and immunotherapy to treat cancer, in particular mesothelioma and lung cancer.
2- Unravelling the cellular and molecular processes that govern successful immunotherapy-induced cancer regression, using systems biology approaches.
3- Identification of the molecular processes that drive mesothelioma invasion using network analysis of high-dimensional molecular data from mouse models and patient samples.
1- Combining chemotherapy and immunotherapy to treat cancer, in particular mesothelioma and lung cancer.
2- Unravelling the cellular and molecular processes that govern successful immunotherapy-induced cancer regression, using systems biology approaches.
3- Identification of the molecular processes that drive mesothelioma invasion using network analysis of high-dimensional molecular data from mouse models and patient samples.
Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.
- 23 Similar Profiles
Neoplasms
Medicine & Life Sciences
Mesothelioma
Medicine & Life Sciences
Immunotherapy
Medicine & Life Sciences
Drug Therapy
Medicine & Life Sciences
gemcitabine
Medicine & Life Sciences
Cross-Priming
Medicine & Life Sciences
Vaccination
Medicine & Life Sciences
Dendritic Cells
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2014 2021
The MexTAg Collaborative Cross: understanding genetic modifiers in mesothelioma
Lake, R., Fisher, S., Lesterhuis, W., Morahan, G., Nowak, A. & Ram, R.
1/05/18 → 30/04/20
Project: Research
Analysis of T cell receptor diversity in animal models of mesothelioma
Lake, R., Chee, H. E. J., Fisher, S., Lesterhuis, W. & Robinson, B.
1/04/18 → 31/03/21
Project: Research
The MexTAg Collaborative Cross
Lake, R., Fisher, S., Lesterhuis, W., Morahan, G., Nowak, A. & Ram, R.
1/02/18 → 31/01/20
Project: Research
Structure-based drug design targeting peroxisome proliferator-activated receptors in mesothelioma
Lesterhuis, W., Piggott, M. & Vrielink, A.
1/01/18 → 30/06/19
Project: Research
Research Output 2008 2018
Combination immune checkpoint blockade as an effective therapy for mesothelioma
Fear, V., Tilsed, C. M., Chee, H. E. J., Forbes, C., Casey, T., Solin, J., Lansley, S., Lesterhuis, W., Dick, I., Nowak, A., Robinson, B., Lake, R. & Fisher, S., 30 Jul 2018, In : Oncolmmunology. 14 p., e1494111.Research output: Contribution to journal › Article
Open Access
Mesothelioma
Neoplasms
Therapeutics
Asbestos
Regulatory T-Lymphocytes
A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice
Aston, W. J., Hope, D. E., Nowak, A. K., Robinson, B. W., Lake, R. A. & Lesterhuis, W. J., 16 Oct 2017, In : BMC Cancer. 17, 1, 684.Research output: Contribution to journal › Article
Open Access
Maximum Tolerated Dose
Drug Therapy
Inbred C57BL Mouse
Dexamethasone
Weight Loss
Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity
Hato, S. V., Figdor, C. G., Takahashi, S., Pen, A. E., Halilovic, A., Bol, K. F., Vasaturo, A., Inoue, Y., Haas, N. D., Verweij, D., Van Herpen, C. M. L., Kaanders, J. H., van Krieken, J. H. J. M., Van Laarhoven, H. W. M., Hooijer, G. K. J., Punt, C. J. A., Asai, A., de Vries, I. J. M. & Lesterhuis, W. J., 1 Jan 2017, In : Oncotarget. 8, 33, p. 54434-54443 10 p.Research output: Contribution to journal › Article
Open Access
File
STAT Transcription Factors
Platinum
Transducers
Cisplatin
Pharmaceutical Preparations
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity
Lesterhuis, W. J., Bosco, A., Millward, M. J., Small, M., Nowak, A. K. & Lake, R. A., Apr 2017, In : Nature Reviews Drug Discovery. 16, 4, p. 264–272Research output: Contribution to journal › Article
Open Access
File
Tumor Biomarkers
Biomarkers
Mathematics
Drug Industry
Therapeutics
Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition
Ebbing, E. A., Steins, A., Fessler, E., Stathi, P., Lesterhuis, W. J., Krishnadath, K. K., Vermeulen, L., Medema, J. P., Bijlsma, M. F. & van Laarhoven, H. W. M., 1 Jul 2017, In : Gastroenterology. 153, 1, p. 63-76.e14Research output: Contribution to journal › Article
TYK2 Kinase
Epithelial-Mesenchymal Transition
Heterografts
Transforming Growth Factor beta
Adenocarcinoma